Patient-reported outcomes with first-line durvalumab, with or without tremelimumab, plus chemotherapy for metastic non-small cell lung cancer

In the multinational phase 3 POSEIDON study, first-line tremelimumab plus durvalumab and chemotherapy significantly improved overall survival and progression-free survival versus chemotherapy alone in metastatic non-small cell lung cancer. Secondary analysis of the study found that these survival improvements were accompanied by significantly delayed deterioration in symptoms, functioning, and global health status/quality of life. The authors conclude that these results support tremelimumab plus durvalumab and chemotherapy as a first-line treatment option in metastatic non-small cell lung cancer.